--- /home/parlparse/parldata/cmpages/wrans/answers2005-10-13a.html	2005-10-17 08:06:34.000527030 +0100
+++ /home/parlparse/parldata/tmp/patchtmp-answers2005-10-13a-mR7okO.html	2005-10-17 08:14:55.000461243 +0100
@@ -1637,7 +1637,7 @@
 
 
 
-<p><a name="qnpa_1">Mr. Salmond: To ask the Secretary of State for Defence what the total spending by his Department on <i>(a)</i> staff, <i>(b)</i> accommodation and <i>(c)</i> procurement in (i) Banff and Buchan and (ii) the North East of Scotland was for the most recent year for which figures are available.  [14889]</p>
+<p><a name="qnpa_1"><b>Mr. Salmond:</b> To ask the Secretary of State for Defence what the total spending by his Department on <i>(a)</i> staff, <i>(b)</i> accommodation and <i>(c)</i> procurement in (i) Banff and Buchan and (ii) the North East of Scotland was for the most recent year for which figures are available.  [14889]</p>
 
 
 
@@ -4099,7 +4099,7 @@
 
 
 
-<p>The National Institute for Health and Clinical Excellence is reviewing its 2001 appraisal of medicines for the treatment of Alzheimer&#039;s disease. As part of this review, the Institute has produced, and consulted on, draft preliminary recommendations that the drugs donepezil, rivastigmine, galantamine and memantine should not be routinely used in treating new patients in the NHS. Following consultation, the institute has deferred publication of its final guidance on these drugs until early next year.
+<p><b>Mr Woodward:</b> The National Institute for Health and Clinical Excellence is reviewing its 2001 appraisal of medicines for the treatment of Alzheimer&#039;s disease. As part of this review, the Institute has produced, and consulted on, draft preliminary recommendations that the drugs donepezil, rivastigmine, galantamine and memantine should not be routinely used in treating new patients in the NHS. Following consultation, the institute has deferred publication of its final guidance on these drugs until early next year.
 </p>
 
 
